Clinical Overview of MDM2/X-Targeted Therapies

MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation and inhibiting its transcriptional activity. Both MDM2 and MDMX function as powerful oncogenes and are commonly ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgess, Andrew, Chia, Kee Ming, Haupt, Sue, Thomas, David, Haupt, Ygal, Lim, Elgene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728205/
https://www.ncbi.nlm.nih.gov/pubmed/26858935
http://dx.doi.org/10.3389/fonc.2016.00007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728205/
https://www.ncbi.nlm.nih.gov/pubmed/26858935
http://dx.doi.org/10.3389/fonc.2016.00007

Ejemplares similares